Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · MAKERS LABORATORIES LTD. · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
MAKERS LABORATORIES LTD.
NSE: MAKERSL · BSE: 506919
NSE: MAKERSL · BSE: 506919
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
MAKERS LABORATORIES LTD.
StateQ4 FY26 filed
Last close · 28 Oct 2026₹188.01
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA42.9 · 0.91 · 7.0
MAKERS LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 127 | 101 | 104 | 121 | 141 |
| EBITDA (ex other income) | 18 | 3 | 1 | 8 | 15 |
| margin % | 14.4 | 3.2 | 1.0 | 6.3 | 10.5 |
| Owners' profit | 5 | (2) | 0 | 7 | 2 |
| EPS, as reported (₹) | 10.12 | (7.90) | (10.62) | 12.70 | 3.99 |
| ROE % · ROCE % | 11.9 · 15.6 | (2.0) · 1.0 | (4.6) · (1.6) | 9.5 · 11.6 | 6.4 · 9.0 |
| Debt / equity (x) | 0.18 | 0.10 | 0.17 | 0.03 | 0.04 |
| Cash from operations | 8 | (9) | 1 | (4) | 14 |
| Capex | (10) | (13) | (7) | (4) | (4) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MAKERS LABORATORIES LTD. · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30 | 30 | 28 | 34 | 35 | 34 | 36 | 36 |
| Profit before tax | (0) | 11 | 1 | 2 | 2 | 1 | 3 | 5 |
| Net profit | (1) | 10 | 0 | 2 | 1 | 1 | 2 | 4 |
| EPS (₹) | (1.67) | 14.94 | (0.50) | 0.08 | 0.74 | 0.20 | 1.59 | 1.85 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceutical | 50 | 35.4 |
| Chemical Manufacturing | 92 | 64.6 |
| Total, before eliminations | 142 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 42.9 | 30.8 | 109 of 158 | 31% |
| P/B | 0.9 | 3.1 | 19 of 163 | 89% |
| ROCE | 8.4 | 10.8 | 111 of 183 | 40% |
| ROE | 6.4 | 9.8 | 109 of 166 | 35% |
| Debt / Equity | 0.0 | 0.2 | 60 of 166 | 64% |
| EBITDA margin | 16.9 | 17.5 | 85 of 165 | 49% |
| Revenue growth | 5.5 | 16.3 | 111 of 161 | 31% |
| Profit growth | 125.2 | 30.9 | 32 of 158 | 80% |
| Market cap | 111 | 806 | 131 of 181 | 28% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MAKERS LABORATORIES LTD. · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 21 Oct 2026 · Board meeting on Nov 4 to consider Q2 FY26-27 results | results | low | — | — |
| 19 Oct 2026 · Saahil Parikh confirmed as Non-Executive Director via postal ballot | board shareholder meetings | medium | — | — |
| 19 Oct 2026 · Postal Ballot: Saahil Parikh Director Appointment Approved | board shareholder meetings | low | — | — |
| 12 Oct 2026 · Routine compliance certificate under SEBI Reg 74(5) for Q2 FY27 | compliance | minimal | — | — |
| 22 Sept 2026 · Trading window closed for insiders ahead of Q2 FY27 results | compliance | minimal | — | — |
| 17 Sept 2026 · Newspaper publication of postal ballot notice and e-voting details | compliance | minimal | — | — |
| 10 Sept 2026 · CEO Saahil Parikh ends executive term, stays on board as Non-Executive Director | management changes | medium | — | — |
| 1 Sept 2026 · CARE reaffirms BBB+ Stable rating on bank facilities | credit debt | medium | — | — |
| 10 Aug 2026 · Makers Labs Q1 FY27 results: Net profit jumps to Rs 459.64 lakh | compliance | minimal | — | — |
| 7 Aug 2026 · AGM 2026: All 4 resolutions passed with over 99% majority | board shareholder meetings | low | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in